

# Joseph Tripodi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8633005/publications.pdf>

Version: 2024-02-01

30  
papers

1,035  
citations

516710

16  
h-index

552781

26  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1813  
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized phase 3 trial of interferon- $\beta$ vs hydroxyurea in polycythemia vera and essential thrombocythemia. <i>Blood</i> , 2022, 139, 2931-2941.	1.4	45
2	Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasmsâ€blast phase. <i>JCI Insight</i> , 2022, 7, .	5.0	3
3	A library of induced pluripotent stem cells from clinically well-characterized, diverse healthy human individuals. <i>Stem Cell Reports</i> , 2021, 16, 3036-3049.	4.8	14
4	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. <i>Blood</i> , 2019, 134, 1498-1509.	1.4	123
5	A Novel t(1;9)(p36;p24.1) JAK2 Translocation and Review of the Literature. <i>Acta Haematologica</i> , 2019, 142, 105-112.	1.4	5
6	Multipotent fetal-derived Cdx2 cells from placenta regenerate the heart. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11786-11795.	7.1	19
7	Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. <i>Blood Advances</i> , 2018, 2, 3581-3589.	5.2	49
8	Genomic characterization of spleens in patients with myelofibrosis. <i>Haematologica</i> , 2018, 103, e446-e449.	3.5	7
9	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). <i>Blood</i> , 2018, 132, 577-577.	1.4	39
10	Reappraising hyalinizing clear cell carcinoma: A populationâ€based study with molecular confirmation. <i>Head and Neck</i> , 2017, 39, 503-511.	2.0	29
11	Analysis of ALK gene in 133 patients with breast cancer revealed polysomy of chromosome 2 and no ALK amplification. <i>SpringerPlus</i> , 2015, 4, 439.	1.2	11
12	Double minute amplification of mutant PDGF receptor $\beta$ in a mouse glioma model. <i>Scientific Reports</i> , 2015, 5, 8468.	3.3	14
13	JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. <i>Blood</i> , 2014, 124, 2987-2995.	1.4	28
14	BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia. <i>Blood</i> , 2013, 121, 1238-1239.	1.4	31
15	Fetal Cells Traffic to Injured Maternal Myocardium and Undergo Cardiac Differentiation. <i>Circulation Research</i> , 2012, 110, 82-93.	4.5	107
16	Oncogene-mediated alterations in chromatin conformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 9083-9088.	7.1	142
17	Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon- $\beta$ 2a specifically targets JAK2V617F-positive polycythemia vera cells. <i>Blood</i> , 2012, 120, 3098-3105.	1.4	55
18	Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. <i>Journal of Clinical Investigation</i> , 2012, 122, 3888-3899.	8.2	74

#	ARTICLE	IF	CITATIONS
19	JAK2 Inhibitors Do Not Affect Stem Cells Present in the Splens of Patients with Myelofibrosis. <i>Blood</i> , 2012, 120, 1752-1752.	1.4	2
20	Development of t(8;21) and RUNX1â€“RUNX1T1 in the Philadelphia-positive clone of a patient with chronic myelogenous leukemia: additional evidence for multiple steps involved in disease progression. <i>Cancer Genetics</i> , 2011, 204, 165-170.	0.4	10
21	Down-regulation of stathmin expression is required for megakaryocyte maturation and platelet production. <i>Blood</i> , 2011, 117, 4580-4589.	1.4	24
22	Multiploid Inheritance of HIV-1 during Cell-to-Cell Infection. <i>Journal of Virology</i> , 2011, 85, 7169-7176.	3.4	150
23	Chromosomal and FISH Study of 286 Patients with Primary Myelofibrosis (PMF) Reveals Cryptic Abnormalities and Identifies Lesions Associated with Favorable Prognosis and Disease Progression., <i>Blood</i> , 2011, 118, 3526-3526.	1.4	0
24	Treatment with Nutlin-3, a Small-Molecule Antagonist of MDM2, in Combination with Low Doses of Pegylated Interferon Alpha 2a Targets Hematopoietic Progenitor Cells From Polycythemia Vera (PV) Patients. <i>Blood</i> , 2011, 118, 796-796.	1.4	0
25	Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. <i>Blood</i> , 2010, 116, 5972-5982.	1.4	27
26	Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia*. <i>British Journal of Haematology</i> , 2010, 151, 288-291.	2.5	21
27	Inversion of Chromosome 12 and Translocations of 12q13-q15 In Primary Myelofibrosis (PMF) Are Associated with Disease Progression and a Poor Prognosis. <i>Blood</i> , 2010, 116, 4110-4110.	1.4	1
28	Recurrent Amplified Regions on the Long Arm of Chromosome 1 (1q) Are Associated with Disease Progression In Ph-Negative Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2010, 116, 3087-3087.	1.4	0
29	The Role of Microtubule Regulatory Protein Stathmin (STMN1) in Megakaryopoiesis.. <i>Blood</i> , 2009, 114, 4591-4591.	1.4	0
30	Contemplations on preclinical validation of fluorescence in situ hybridization probe assay for paraffin-embedded tissues in hematologic disorders. <i>Cancer Genetics and Cytogenetics</i> , 2008, 183, 1-5.	1.0	5